Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs

D. Summer, S. Mayr, M. Petrik, C. Rangger, K. Schoeler, L. Vieider, B. Matuszczak, C. Decristoforo,

. 2018 ; 11 (4) : . [pub] 20181011

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001647

The inverse electron-demand Diels-Alder reaction between 1,2,4,5-tetrazine (Tz) and trans-cyclooct-2-ene (TCO) has gained increasing attraction among extensive studies on click chemistry due to its exceptionally fast reaction kinetics and high selectivity for in vivo pretargeting applications including PET imaging. The facile two-step approach utilizing TCO-modified antibodies as targeting structures has not made it into clinics yet. An increase in the blood volume of humans in comparison to mice seems to be the major limitation. This study aims to show if the design of multimeric Tz-ligands by chelator scaffolding can improve the binding capacity and may lead to enhanced PET imaging with gallium-68. We utilized for this purpose the macrocyclic siderophore Fusarinine C (FSC) which allows conjugation of up to three Tz-residues due to three primary amines available for site specific modification. The resulting mono- di- and trimeric conjugates were radiolabelled with gallium-68 and characterized in vitro (logD, protein binding, stability, binding towards TCO modified rituximab (RTX)) and in vivo (biodistribution- and imaging studies in normal BALB/c mice using a simplified RTX-TCO tumour surrogate). The 68Ga-labelled FSC-based Tz-ligands showed suitable hydrophilicity, high stability and high targeting specificity. The binding capacity to RTX-TCO was increased according to the grade of multimerization. Corresponding in vivo studies showed a multimerization typical profile but generally suitable pharmacokinetics with low accumulation in non-targeted tissue. Imaging studies in RTX-TCO tumour surrogate bearing BALB/c mice confirmed this trend and revealed improved targeting by multimerization as increased accumulation in RTX-TCO positive tissue was observed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001647
003      
CZ-PrNML
005      
20190115105653.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ph11040102 $2 doi
035    __
$a (PubMed)30314332
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Summer, Dominik $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. dominik.summer@i-med.ac.at.
245    10
$a Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs / $c D. Summer, S. Mayr, M. Petrik, C. Rangger, K. Schoeler, L. Vieider, B. Matuszczak, C. Decristoforo,
520    9_
$a The inverse electron-demand Diels-Alder reaction between 1,2,4,5-tetrazine (Tz) and trans-cyclooct-2-ene (TCO) has gained increasing attraction among extensive studies on click chemistry due to its exceptionally fast reaction kinetics and high selectivity for in vivo pretargeting applications including PET imaging. The facile two-step approach utilizing TCO-modified antibodies as targeting structures has not made it into clinics yet. An increase in the blood volume of humans in comparison to mice seems to be the major limitation. This study aims to show if the design of multimeric Tz-ligands by chelator scaffolding can improve the binding capacity and may lead to enhanced PET imaging with gallium-68. We utilized for this purpose the macrocyclic siderophore Fusarinine C (FSC) which allows conjugation of up to three Tz-residues due to three primary amines available for site specific modification. The resulting mono- di- and trimeric conjugates were radiolabelled with gallium-68 and characterized in vitro (logD, protein binding, stability, binding towards TCO modified rituximab (RTX)) and in vivo (biodistribution- and imaging studies in normal BALB/c mice using a simplified RTX-TCO tumour surrogate). The 68Ga-labelled FSC-based Tz-ligands showed suitable hydrophilicity, high stability and high targeting specificity. The binding capacity to RTX-TCO was increased according to the grade of multimerization. Corresponding in vivo studies showed a multimerization typical profile but generally suitable pharmacokinetics with low accumulation in non-targeted tissue. Imaging studies in RTX-TCO tumour surrogate bearing BALB/c mice confirmed this trend and revealed improved targeting by multimerization as increased accumulation in RTX-TCO positive tissue was observed.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mayr, Sonja $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. sonja.mayr@student.uibk.ac.at.
700    1_
$a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZE-77900 Olomouc, Czech Republic. milos.petrik@seznam.cz.
700    1_
$a Rangger, Christine $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. christine.rangger@i-med.ac.at.
700    1_
$a Schoeler, Katia $u Biocenter-Division of Developmental Immunology, Medical University of Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria. katia.schoeler@i-med.ac.at.
700    1_
$a Vieider, Lisa $u Institute of Pharmacy, Pharmaceutical Chemistry, University of Innsbruck, Center for Chemistry and Biomedicine (CCB), Innrain 80/82, A-6020 Innsbruck, Austria. lisa.vieider@student.uibk.ac.at.
700    1_
$a Matuszczak, Barbara $u Institute of Pharmacy, Pharmaceutical Chemistry, University of Innsbruck, Center for Chemistry and Biomedicine (CCB), Innrain 80/82, A-6020 Innsbruck, Austria. barbara.matuszczak@uibk.ac.at.
700    1_
$a Decristoforo, Clemens $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. clemens.decristoforo@i-med.ac.at.
773    0_
$w MED00184066 $t Pharmaceuticals (Basel, Switzerland) $x 1424-8247 $g Roč. 11, č. 4 (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30314332 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190115105903 $b ABA008
999    __
$a ind $b bmc $g 1365456 $s 1039770
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 11 $c 4 $e 20181011 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace